TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04450849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided tissue regeneration with using an absorbable collagen membrane associated with inorganic bovine bone associated.
Description: Dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) associated with inorganic bovine bone associated with collagen matrix (Bio-Oss® Collagen).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: guided tissue regeneration with using an absorbable collagen membrane associated or not with inorganic bovine bone associated with collagen matrix.
Description: dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) alone.
Study: NCT03746548

Intervention type: DEVICE
Group type: OTHER
Intervention: Adhear
Description: Patients are wearing the Adhesive bone conduction hearing device (Adhear) for 2 weeks
Study: NCT03052491

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stem Cell 100+
Description: Open-Label 10-Component Dietary Supplement
Study: NCT03228264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: teleSLT
Description: The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: teleSLT
Description: The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).
Study: NCT03746548

Intervention type: DEVICE
Group type: OTHER
Intervention: Adhear
Description: Patients are wearing the Adhesive bone conduction hearing device (Adhear) for 2 weeks

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact Mini (CM)
Description: Patients are wearing the Conventional bone conduction hearing device (Contact Mini) for 2 weeks

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact Mini (CM)
Description: Patients are wearing the Conventional bone conduction hearing device (Contact Mini) for 2 weeks
Study: NCT02307214

Intervention type: OTHER
Group type: OTHER
Intervention: BaroReflex Sensitivity, endothelial function measurement
Description: no other

Intervention type: OTHER
Group type: OTHER
Intervention: BaroReflex Sensitivity, endothelial function measurement
Description: no other

Intervention type: OTHER
Group type: OTHER
Intervention: BaroReflex Sensitivity, endothelial function measurement
Description: no other
Study: NCT03228264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: teleCT
Description: For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: teleCT
Description: For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.
Study: NCT00750997

Intervention type: DRUG
Intervention: hypertonic saline
Description: patients in parent trial were randomized to 250cc 7.5% saline, 7.5%saline with 6%dextran or normal saline as control as the initial resuscitation fluid after injury with signs of either hemorrhagic shock or severe traumatic brain injury
Study: NCT01258582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral HIV screening
Description: Participants will undergo oral HIV screening and, if positive, further study visits for up to 6 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fingerstick HIV screening
Description: Participants will undergo fingerstick HIV screening and, if positive, further study visits for up to 6 months
Study: NCT03807518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Exercise Program
Description: Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing neo adjuvant therapy and for a six week period when deemed fit post surgery.
Study: NCT01431170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besivance Treatment Group
Description: Subjects Receive Besivance™ ophthalmic suspension, 0.6% one drop in the study eye three times daily (TID) for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polytrim Treatment Group
Description: Subjects receive Polytrim ophthalmic solution one drop in the study eye three times daily (TID) for 10 days.
Study: NCT01700426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: A commercial Vitamin E preparation (Aqueous Vitamin E®, 15 IU/0.3 ml; SilaRx, Inc, Spring Valley, NY) will be used for the study, also on the recommendation of the Children's Hospital Colorado (CHC) research pharmacist. The Vitamin E dose will be 18 mg/day for all subjects randomized to the Vitamin E group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The control group will receive an indistinguishable placebo preparation, which will be compounded by the CHC research pharmacy using the following inactive ingredients: purified water, polysorbate 80, sorbital, and propylene glycol. This suspension is stable for 6 months.
Study: NCT03119974

Intervention type: DRUG
Group type: OTHER
Intervention: Tpo-RA discontinuation
Description: a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (\> 2 months) complete response (platelets counts \> 100 x 109/L) period on Tpo-RA treatment.
Study: NCT01978210

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wireless Moisture Pager (WMP)
Description: The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless Moisture Pager (WMP)
Description: The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.
Study: NCT00786422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.
Study: NCT04255615

Intervention type: OTHER
Group type: OTHER
Intervention: AI to analyze 3 D ultrasound
Description: AI to assess 3 D ultrasound to assess antral follicle count
Study: NCT02156141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised high intensity training
Description: 8 weeks of supervised training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optional training
Description: 8 weeks of optional training on cycle ergometer. No program needs to be followed. Participant decides whether they want to keep training or not.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control period
Description: 8 weeks with no training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsupervised High intensity training
Description: 8 weeks of unsupervised high intensity training.
Study: NCT03421782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Undergo PROSPECT internet-based CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo POWER exercise intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo POWER exercise intervention
Study: NCT04387682

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: β-glucan
Description: β-glucan, a biological response regulator, derived from yeast has been known for more than 45 years, and has anti-infective and anti-tumor activities. β-glucan is a molecule with a β-1,3-linked D-glucose backbone and β-1,6-linked side chains. Thus far, at least 4 receptors for β-glucan have been discovered in humans, which are surface antigens associated with macrophages or myeloid precursor cells as complement receptor 3 (CR3; CD11b/CD18, Mac-1, αMβ2 integrin) (Vetvicka et al. 1996; Xia et al. 1999), lactosylceramide (Zimmerman et al. 1998), scavenger receptor (Rice et al. 2002) and dectin-1 (Brown et al. 2003; Taylor et al. 2007; Saijo et al. 2007).
Study: NCT03293173

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: R-CHOEP
Description: rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Description: dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab
Study: NCT00750646

Intervention type: DEVICE
Intervention: MEMS cap
Description: The Medication Event Monitoring System will be used to assess the level of subject adherence to recommended topical eye drop therapy.
Study: NCT03627234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Same Day Discharge
Description: Patients will be randomized to same day discharge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overnight Stay
Description: Patients will be randomized to stay overnight
Study: NCT04103021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Port-A-Cath
Description: Totally implanted central venous access device
Study: NCT01031888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical insulin eye drops
Description: Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical insulin eye drops
Description: Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional postoperative eye drops
Description: topical steroid, antibiotic and mydriatics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional postoperative eye drops
Description: topical steroid, antibiotic and mydriatics
Study: NCT01746290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PulsePoint notification
Description: When the smartphone receives the alert data, the phone alarms with auditory, tactile (vibration) and visual stimuli (Figure 1). After acknowledgement of the alert by the user, the application presents a map and text information to direct the user to the exact location of the emergency. Using local AED registry data, the application can also reveal exact AED locations in the vicinity of the emergency
Study: NCT03555058

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment escalation
Description: Treatment escalation per TDM and physician's decision.
Study: NCT01497756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAPP use
Description: Any abdominal pelvic pressure
Study: NCT02866812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires assessing the state of fatigue, depression and anxiety
Study: NCT01242514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 100mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 150mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 100mg once daily
Study: NCT03051958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet mindfulness&exposure treatment
Description: See description under Arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Written information about standard treatment for atopic dermatitis, that is information regarding how to use moisturizers and anti-inflammatory treatment such as Topical steroids.
Study: NCT04561856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous 4mg
Study: NCT01087762

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo to CZP injection.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo to CZP injection.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo to CZP injection.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo to CZP injection.
Study: NCT00681525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: One ABT-335 135 mg capsule QD for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: One ABT-335 135 mg capsule QD for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: One 80 mg tablet of atorvastatin QD for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: One 80 mg tablet of atorvastatin QD for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: One ezetimibe 10 mg tablet QD for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: One ezetimibe 10 mg tablet QD for 10 days
Study: NCT01865253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal Denervation
Study: NCT00944372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium In-111 pentetreotide
Description: Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium In-111 pentetreotide
Description: Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium In-111 pentetreotide
Description: Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
Study: NCT02559713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion
Study: NCT02225574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK-162
Description: Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle.
Study: NCT00944372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium In-111 pentetreotide
Description: Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium In-111 pentetreotide
Description: Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium In-111 pentetreotide
Description: Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium In-111 pentetreotide
Description: Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
Study: NCT03356028

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Child and adolescent psychiatry and Epidemiology
Description: psychosocial risk assessment questionnaire, structured diagnostic interview, pedopsychiatric questionnaire
Study: NCT03553212

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: 20-23 Gy in 2 fractions on the whole prostate gland +/- seminal vesicles and 24-27 Gy in 2 fractions as simultaneous integrated boost (SIB) on the dominant intraprostatic lesion (DIL) 2 weeks in all.
Study: NCT02918279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Administered once daily subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once daily subcutaneously (s.c., under the skin)
Study: NCT02949583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Punica granatum Linn.
Description: Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
Study: NCT02748954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thoughts
Description: Thoughts. Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activities.
Description: Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertiveness.
Description: Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene
Description: Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Own Methods
Description: wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
Study: NCT02847702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM902A 200-mg Capsules
Description: Taken orally with food twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM902A 400-mg Capsules
Description: Taken orally with food twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500-mg Capsules
Description: Taken orally with food twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules to match VM902A and/or naproxen taken orally with food twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules to match VM902A and/or naproxen taken orally with food twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules to match VM902A and/or naproxen taken orally with food twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules to match VM902A and/or naproxen taken orally with food twice daily
Study: NCT05188781

Intervention type: DRUG
Intervention: Pembrolizumab combined Anlotinib
Description: Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off